Skip to main content

Table 3 Distribution of lymphatic invasion density (LID [nLI/mm2]), peritumoral lymphatic vascular density (P-LVD), and intratumoral lymphatic vascular density (I-LVD) according to clinicopathologic parameters in cases with gastric carcinoma

From: Inducible nitric oxide synthase expression in gastric adenocarcinoma: impact on lymphangiogenesis and lymphatic metastasis

Variables

Mean ± SD (Min.-Max.)

LID

P-LVD

I-LVD

Histological type

NOS/tubular/papillary

0.06 ± 0.16 (0–0.8)

12.8 ± 2.7 (7.2–15.7)

6.9 ± 4.4 (1–24.3)

Mucinous/poorly cohesive

0.11 ± 0.13 (0–0.8)

13.8 ± 5.4 (5.9–21.6)

6.9 ± 2.6 (3.5–10)

Differentiation

Well/moderate

0.01 ± 0.01 (0–0.03)

10.2 ± 2.7 (7.2–15.7)

5.2 ± 2.1 (1–8.7)

Poorly/signet ring cell

0.10 ± 0.18 (0–0.88)

14.5 ± 6.2 (5.7–32)

6.9 ± 2.6 (3.5–10.2)

pN

N0

0.001 ± 0.003 (0–0.03)

8.1 ± 1.7 (5.9–11.7)

3.5 ± 1.5 (1–5.5)

N1

0.02 ± 0.01 (0–0.04)

8.6 ± 1.9 (5.7–11)

4.8 ± 1.9 (3–8.7)

N2

0.03 ± 0.03 (0–0.02)

12..6 ± 2.5 (9–17.5)

6.8 ± 1.9 (3.5–9.3)

N3

0.18 ± 0.2(0–0.9)

19.1 ± 5.3 (13.7–32)

10.6 ± 4.4 (6–24.3)

pT

0.001 ± 0.003 (0–0.03)

8.1 ± 1.7 (5.9–11.7)

3.5 ± 1.5 (1–5.5)

T1

0.0 ± 0.0 (0–0)

7.9 ± 1.1 (7.2–8.7)

3.9 ± 0.6 (3.4–4.3)

T2

0.0 ± 0.01 (0–0.01)

10.8 ± 7.2 (5.7–16)

6.4 ± 3.2 (4.1–8.7)

T3

0.04 ± 0.05 (0–0.27)

11.8 ± 4.1 (5.9–22.1)

5.9 ± 2.8 (1–11.3)

T4

0.16 ± 0.3 (0–0.88)

19.1 ± 5.3 (13.7–32)

9.6 ± 5.2 (4.3–24.3)

TNM stage

I

0.0 ± 0.0 (0–0)

7.7 ± 0.9 (7.2–8.7)

2.9 ± 1.7 (1–4.3)

II

0.01 ± 0.02 (0.0–0.05)

9.5 ± 2.9 (5.7–16)

4.6 ± 1.9 (1.1–8.7)

III

0.13 ± 0.2 (0.01–0.88)

16.2 ± 5.6 (9–32)

9 ± 4.2 (7.9–11.5)

IV

-

-

-

Total

0.07 ± 0.15 (0–0.88)

13.1 ± 5.7 (5.7–32)

6.9 ± 3.9 (1–24.3)